Lifevantage Corporation Common Stock (Delaware) (LFVN)
Stock · NASDAQ · Health Care
$6as of 10/16/2026
Price chart
Active signals
LFVN Signal Track Record
How signals performed across all stocks →What LFVN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +1.3% | 53% | September 11, 2026 |
| Bollinger Band Breakout | 26 | +0.6% | 50% | July 24, 2026 |
| Bollinger Band Breakdown | 23 | +3.6% | 61% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +12.0% | 75% | July 9, 2026 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, an…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 209
- Website
- www.lifevantage.com/
Fundamentals
- 1-day range
- $5.8$6.1
- Market cap
- $83.01M
- P/E (trailing)
- 14.40
- P/E (forward)
- 15.52
- EPS (trailing)
- $0.40
- Dividend yield
- 2.41%
- Beta
- 0.76
- Avg. volume
- 50.8K
- Ex-dividend date
- September 1, 2026
- Dividend pay date
- September 15, 2026
How Lifevantage Corporation Common Stock (Delaware) Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Aug 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Lifevantage Corporation Common Stock (Delaware) Competitors
Chosen by industry and closest market cap.
- LFVNLifevantage Corporation Common Stock (Delaware)$6▲ 0.00%Market cap $83.01MP/E 14.40$3.9$11.71
- ATHEAlterity Therapeutics Limited American Depositary Shares$2.62▼ 3.68%Market cap $82.65MP/E —$0.01$0.785
- TELOTelomir Pharmaceuticals Inc. Common Stock$1.05▲ 0.00%Market cap $80.47MP/E —$0.8884$1.75
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.40 | $6 | ▲ 0.00% | $3.9$11.71 |
| ATHE Alterity Therapeutics Limited American Depositary Shares | $82.65M | — | $2.62 | ▼ 3.68% | $0.01$0.785 |
| TELO Telomir Pharmaceuticals Inc. Common Stock | $80.47M | — | $1.05 | ▲ 0.00% | $0.8884$1.75 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- LifeVantage Unveils Turnaround Plan to Rebuild Brand, Margins and GrowthYahoo · 9/24/2026
- LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026Yahoo · 9/18/2026
- Kristen Cunningham Takes Money Off The Table, Sells $55K In Lifevantage StockBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Kristen Cunningham · October 7, 2026 · Grant49.3K
- Kristen Cunningham · October 7, 2026 · Grant32.9K
- Carl Aure · October 7, 2026 · Grant53.6K
- Carl Aure · October 7, 2026 · Grant35.7K
- Terrence Moorehead · October 7, 2026 · Grant289.9K
- Terrence Moorehead · October 7, 2026 · Grant193.2K
- Kristen Cunningham · October 1, 2026 · Tax Withholding637 @ $6.24
- Carl Aure · October 1, 2026 · Tax Withholding460 @ $6.24
- Darwin Lewis · September 15, 2026 · Buy976 @ $6.22
- Kristen Cunningham · September 14, 2026 · Sale8.9K @ $6.18
- Kristen Cunningham · September 11, 2026 · Sale100 @ $6.41
- Kristen Cunningham · September 10, 2026 · Tax Withholding2.3K @ $6.37
- Carl Aure · September 10, 2026 · Tax Withholding1.9K @ $6.37
- Terrence Moorehead · August 6, 2026 · Grant540.1K
- Terrence Moorehead · August 6, 2026 · Grant308.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 7.57M
- Total value held
- $32.48M
- Institutional holders
- 99
- Unknown2.44M
- Unknown867.7K
- Unknown769.7K
- Unknown429.4K
- Unknown276.2K
- Unknown261.2K
- Unknown219.2K
- Unknown185.1K
- Unknown167.1K
- Unknown156.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
LifeVantage Announces Turnaround Plan to Revitalize Brand and Margins
LifeVantage announced a turnaround plan aimed at rebuilding its brand, improving margins, and driving growth. The announcement may influence investor perception as the company seeks to strengthen its financial performance. The move comes as the stock trades near its 25‑touch support level at $6.22.
LifeVantage Announces Turnaround Plan to Revitalize Brand and Margins. LifeVantage announced a turnaround plan aimed at rebuilding its brand, improving margins, and driving growth. The announcement may influence investor perception as the company seeks to strengthen its financial performance. The move comes as the stock trades near its 25‑touch support level at $6.22.